|Growth of nanoparticles by radical-starved-feed polymerization of technical dispersions is studied with photon density wave spectroscopy Source: Onlinelibrarywiley.com|
Nanoparticle delivery platforms could increase our ability to rapidly target and treat deliberate diseases for which there currently is no treatment, and in many instances, no vaccine available due to a number of both technical and cost related issues. Category A agents and those suitable for biological warfare, often have no vaccine candidates, due to lack of funding, investment, research and development. Nanoparticle platforms could reduce several inhibitors often cited as reasons for lack of R and D. Moreover, the development of such platforms would likely offer swift treatment vs. often delayed treatment which compromises the patient. Several pharmaceutical firms are currently working with nanoparticle vaccine drug delivery platforms and recombinant NP vaccines. Moving from nanoparticle delivery platforms to NP vaccine development, Novavax for example is working on recombinant nanoparticle vaccines.
Novavax describes their recombinant NP vaccine technology: "Unlike traditional vaccines that are based on killed viruses or live, attenuated viruses, Novavax uses recombinant technology that allows us to customize the components of our vaccine candidates in order to solve challenges presented by novel infectious diseases. For example, in the event of a pandemic influenza threat caused by a new influenza strain, our scientists will be able to utilize the genetic code of the novel pandemic influenza viruses provided by the World Health Organization and produce, in a matter of weeks, a vaccine candidate designed to generate protective immunity to specifically target that novel virus. Generally our vaccines are composed of one or more critical surface proteins of the specific virus or pathogen we are targeting. In the case of influenza, Novavax' influenza vaccines contain the important surface proteins known as hemagglutinin and neuraminidase. These proteins are designed to induce immunity in the vaccine recipient, which neutralizes the virus and creates protection against further exposure to the disease." See: http://www.novavax.com/go.cfm?do=Page.View&pid=3
While there are many very promising pharmaceuticals working in the field of NP vaccines and delivery platforms, Novavax and Medicago are certainly the forerunners in my view, with impressive results to date in this field.
Dr.Jill Bellamy is an internationally recognized expert on biological warfare and defence. She has formerly advised NATO and for the past seventeen years has represented a number of bio-pharmaceutical and government clients working on procurement strategy between NATO MS and Washington DC. Her private government relations consultancy Warfare Technology Analytics is based in the Netherlands. Dr. Bellamy's articles have appeared in the National Review, The Wall Street Journal, The Washington Post, The Sunday Times of London, Le Temps, Le Monde and the Jerusalem Post among other publications. She is a CBRN SME with the U.S. Department of Defence, Chemical, Biological, Radiological and Nuclear Defence Information Analysis Center and CEO of Warfare Technology Analytics.